R-2487 is under clinical development by Rise Therapeutics and currently in Phase I for Rheumatoid Arthritis. According to GlobalData, Phase I drugs for Rheumatoid Arthritis have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how R-2487’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
R-2487 overview
R-2487 is under development for the treatment of rheumatoid arthritis, type 1 diabetes, multiple sclerosis and Sjogren's syndrome. It is administered orally. The therapeutic candidate is a genetically modified organism (GMO) and single strain of L. lactis that expresses functional CFA/I from a genome-integrated expression operon. It is developed based on TriPartite X (TPX) platform technology.
Rise Therapeutics overview
Rise Therapeutics is a biopharmaceutical company that develops immunological-based biologics to treat immunology and inflammatory indications. Its pipeline product portfolio includes R-3750, R-2487, R-5780 and others. The company’s R-2487 an immunobiotic drug targeting key immunological pathways that induce specific populations of T regulatory cells to intervene with inflammatory processes; R-3750 is an immunobiotic program that induces immune homeostasis and enhances the gut barrier for the treatment of gastrointestinal (GI) inflammatory disease. Its oral delivery platform, TriPartite X (TPX) is a novel DNA assembly approach that allows the creation of recombinant probiotics to escort targeted protein therapies to the site of action, the intestinal space. Rise Therapeutics is headquartered in Rockville, Maryland, the US.
For a complete picture of R-2487’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
